By utilizing RKO colon cancer cell line, we discovered that in response to PMA, a significant increase in MMP13 enzymatic activity was recorded with a dose-dependent decrease in response to MMP13 inhibitor WAY-170523 (Cat.# 2633, TOCRIS Biosciences; Fig 4B). This evidence concerns the gene MMP13 and colonic neoplasm.